The AI buildout is still pulling enormous amounts of capital toward chips, data centers, and frontier models, but the risks around that spending are becoming harder to ignore. Regulators are also paying closer attention to leverage, valuations, and whether the growth stories attracting billions of dollars are backed by durable demand.
Elon’s AI Plan (Sponsored)
James Altucher just uncovered an FCC filing Elon’s been keeping quiet about…
And believes it’s part of the biggest wealth creation event in history.
This project would allow Elon to control the AI Industry from end to end… and could create 1,806,000 new millionaires over the coming decade starting September 25.
Want your shot to become one of them?
Get James’ entire briefing about the situation AND details about the $100 stock at the center of it all right here.
Futures at a Glance📈
Futures are pushing higher to start the week, with tech leading as oil prices retreat and ease some inflation pressure. Treasury yields remain jumpy after last week’s Fed hike, while traders turn their attention to fresh U.S.-China talks and the outlook for further tightening.
Want to make sure you never miss a pre-market alert?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.
Email’s great. Texts are faster.
You’ll be first in line when the market starts moving.
What to Watch
Earnings (Aftermarket):
· Abivax SA [ABVX]
Earnings (Time Not Supplied):
· Grifols, S.A. [GRFS]
· ChronoScale Holdings Corporation [CHRN]
· Currenc Group Inc. [CURR]
· Apartment Investment and Management Company [AIV]
· CBAK Energy Technology Limited [CBAT]
· AiRWA Inc. [YYAI]
· Freight Technologies, Inc. [FRGT]
Economic Reports:
· None scheduled
Elite Trade Club Insider
A New CEO Bought $1 Million While A Biotech Founder Sold Nearly $11 Million
You’re looking at one regional banking giant entering a new leadership era and one biotech company spending heavily to build its post-COVID oncology future. Elite Trade Club Insider readers are seeing how the people closest to those stories are positioning: a newly appointed CEO put $1.02 million of fresh cash into his stock, while a biotech founder sold nearly $11 million through a plan established months ago.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
Market Pulse
Asian tech stocks started the week higher as AI-driven data demand lifted chipmakers across South Korea and Taiwan; U.S. futures also gained, even as bond markets continue pricing the possibility of additional Fed hikes this year.
The Fed and Bank of England are digging into Wall Street’s leverage risks after Jane Street reportedly took a $15 billion hit tied to the collapse of an AI-focused hedge fund, prompting questions about banks’ exposure to large trading firms.
AI & Infrastructure
Taiwan just broke ground on another critical piece of the AI supply chain with a new advanced-packaging park anchored by TSMC; the site will help suppliers test technologies used to package chips from Nvidia, AMD, and Broadcom.
SoftBank is borrowing more than $10 billion to fund its OpenAI bet through new dollar- and euro-denominated bond offerings, replacing a bridge loan ahead of its next $10 billion investment payment due in October.
Robotics & Healthcare
China is cooling its humanoid-robot IPO frenzy as regulators raise scrutiny around valuations and revenue quality; Unitree has already fallen 55% from its post-listing peak, while investors increasingly want evidence of real commercial demand.
Novo Nordisk is under pressure to find a growth engine beyond Wegovy as investors push management for a clearer post-semaglutide strategy; Lilly’s Zepbound is expected to outsell Wegovy this year while key patents approach expiration next decade.
This Month’s Watchlist (Sponsored)
A newly released report highlights seven stocks chosen for their near-term potential.
Selections are based on a mix of technical and fundamental indicators.
While past picks have performed well, future results are uncertain.
The report is available for a limited time.
Access the free report.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Media & Deals
Paramount could spend $1.5 billion in California to save its Warner Bros. Discovery deal as settlement talks move toward potential concessions on production, studio ownership, cable assets, and CNN oversight for the proposed $110 billion merger.
Sazerac is taking another European spirits brand private with a takeover offer for Germany’s Berentzen at €5.55 per share; the U.S. drinks group expects to delist the company after completing the acquisition.
Capital & IPOs
Four Chinese companies are chasing $1.83 billion in Hong Kong listings as RoboTechnik leads a fresh wave of offerings; the AI-infrastructure supplier alone could raise more than $650 million if its full allotment is exercised.
Moneyview is shrinking its IPO ambitions before going public with the Accel-backed fintech now targeting a valuation around $624 million after cutting both the fresh share issuance and the number of shares existing investors plan to sell.
Which do you trust more?
Movers and Shakers
Accenture [ACN]: Premarket Move: +6%
Accenture jumped after announcing a major AI safety partnership with Anthropic. The companies each plan to invest at least $1 billion over five years, with Accenture deploying embedded teams to evaluate and stress-test Anthropic’s AI models, giving the consulting giant a potentially lucrative new role as demand for independent AI oversight grows.
USA Rare Earth [USAR]: Premarket Move: +6%
USA Rare Earth climbed as Chinese rare-earth magnet shipments to the U.S. fell sharply ahead of this week’s Trump-Xi summit. August shipments dropped roughly 20% from July, reinforcing concerns about U.S. dependence on Chinese supply and strengthening the strategic case for domestic producers such as USA Rare Earth as Washington pushes to build a more secure mine-to-magnet supply chain.
Amneal Pharmaceuticals [AMRX]: Premarket Move: −5%
Amneal pulled back as traders took profits following a strong multi-day run, despite Friday’s FDA approval and immediate launch of its lanreotide injection. The reference drug generated roughly $983 million in U.S. sales over the past year, but Amneal shares had already climbed sharply heading into Monday, including an 8.6% surge earlier in the week, leaving the stock vulnerable to some profit-taking.
Gold Moves Quietly (Sponsored)
Central banks have been accumulating gold while many Americans are asking the same question: what happens to retirement savings if the dollar keeps losing purchasing power?
A free new briefing looks at why gold has returned to the spotlight, what investors learned from the monetary changes of the 1970s, and where physical gold may fit in a long-term retirement plan.
It also explains one way eligible retirement savings can potentially be repositioned without an immediate tax hit.
Get the Free Gold Retirement Briefing and See Your Options
*Reagan Gold Group does not provide financial, legal, or tax advice. This information is for educational purposes only and should not be considered investment advice. All investments carry risk, including loss of principal. Past performance is not indicative of future results. Consult your licensed financial advisor before making investment decisions.
Everything Else
🚀 Seven stocks are quietly doing what the Mag 7 did early on, and analysts believe they are already positioned to define the next phase of market leadership.
🍸 German spirits maker Berentzen jumped after U.S.-based Sazerac launched a takeover bid at €5.55 per share, with management backing the offer.
💊 Novo Nordisk is facing fresh pressure to diversify beyond obesity drugs after recent trial setbacks and growing competition from Eli Lilly.
🤖 China is slowing humanoid-robot IPOs after Unitree Robotics’ volatile debut raised concerns that valuations are running ahead of commercial demand.
⛏️ MP Materials is in focus after China Rare Earth Group entered talks to buy Shenghe Resources, which owns a stake in the U.S. rare-earth producer.
You Read This Far. Here's Where the Real Work Lives.
We run three live portfolios on Autopilot, and everything about them is public: every position, every allocation, every trade, visible the moment it happens.
We keep our own money in each one, because analysis you won't fund yourself is just content.
THE UNBREAKABLE STACK
Our growth book: durable software and cybersecurity names built to compound quietly for years.
THE HORMUZ PREMIUM
Our energy thesis: built for how that sector actually pays, over quarters, not headlines.
THE ELON INDEX
Our conviction bet on the Musk universe: Tesla, and the companies orbiting his ventures, energy, AI, infrastructure. High-beta by design, for investors who want direct exposure to the trade rather than watching it from the sidelines.
And here's the part that makes it effortless: Autopilot does the trading for you. Connect the brokerage you already use (Robinhood, Schwab, Fidelity, and more) and every move we make gets mirrored in your own account automatically.
Your money never leaves your brokerage. It stays in your account, under your control, and you can override any trade or disconnect anytime. Autopilot even rebalances automatically when allocations drift, and you get a notification every time something happens.
No watching tickers. No timing entries. No fat-finger mistakes at market open. You pick the portfolio, we do the work, your account follows along.
Pick the one that fits your risk level, or run all three:
Live portfolios, real positions, our own capital at stake. Your funds stay in your own brokerage account. Past performance doesn't guarantee future results.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
